EORTC Lung Cancer Group studying potential new indication for pazopanib for patients with non-small cell lung cancer
11 Jan 2013
Approximately half of all non-small cell lung cancer (NSCLC) patients are diagnosed at an advanced stage, and the treatment option for these patients is palliative chemotherapy. It has been shown that palliative chemotherapy can lead to improvements in survival and quality-of-life measures, but due to cumulative toxicity, guidelines limit the duration of treatment with currently available agents. The continuation of treatment at the end of a definite number of chemotherapy cycles (maintenance treatment) is an approach that has been widely studied in order to improve outcome in NSCLC.
The randomized phase III EORTC 08092 MAPPING trial will investigate the therapeutic benefit of pazopanib as maintenance treatment in 587 patients with advanced stage NSCLC. Pazopanib targets endothelial growth factor receptors involved in angiogenesis and has the potential of being effective in combatting NSCLC.
Pazopanib was approved by the U.S. Food and Drug Administration for the treatment of patients with advanced renal cell carcinoma as well as for patients with advanced soft tissue sarcoma who have received prior chemotherapy, and has been shown to prolong progression free survival in patients with advanced soft-tissue sarcoma.
Dr. Mary O’Brien of the Royal Marsden Hospital, Chair of the EORTC Lung Cancer Group, and Coordinator of this study says, “We need well tolerated active, preferably oral, forms of maintenance therapy – this agent could fit the bill.”
This trial is currently open in France, Belgium, the United Kingdom, The Netherlands, Greece, Slovenia, Egypt, and Germany. Two sites in Poland and one site in Cyprus will soon join the trial, and there are plans to open four additional sites in the United Kingdom, one in Belgium, and one in Slovenia. This trial is supported by an educational grant from GlaxoSmithKline.
For more information concerning this trial please contact: www.eortc.org/contact
John Bean
EORTC, Medical Science Writer
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023